Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
Public ClinicalTrials.gov record NCT00031187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
Study identification
- NCT ID
- NCT00031187
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2000 (Type not available)
- Primary completion
- Not listed
- Completion
- Jul 2003 (Actual)
- Last update posted
- Oct 24, 2011
2000 – 2003
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72764 | — |
| West Los Angeles - VA Healthcare Center | Los Angeles | California | 90073 | — |
| VA Medical Center of Palo Alto | Palo Alto | California | 94304 | — |
| Sharp HealthCare, Sidney Kimmel Cancer Center | San Diego | California | 92121 | — |
| Bendheim Cancer Center | Greenwich | Connecticut | 06830 | — |
| Broward Oncology Associates | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Innovative Medical Research of South Florida | Miami Shores | Florida | 33138 | — |
| St. Joseph Mercy Oakland Hospital | Pontiac | Michigan | 33308 | — |
| Arlington Fairfax Hematology-Oncology, P.C. | Arlington | Virginia | 22205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00031187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2011 · Synced Oct 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00031187 live on ClinicalTrials.gov.